Oncoinvent ASA
The answer first
Does Oncoinvent beat the market?
Yes, Oncoinvent has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 36% of Nordic stocks
- Quality65
- Value3
- Trend66
No. 89 of 195 in healthcare
Max for seven days
Follow Oncoinvent with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Oncoinvent
Your first answer is free, no account needed.
Do you own Oncoinvent, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Oncoinvent and a few more. Free, no card.
Super Stock+44.6%In short
- Oncoinvent has risen 41.8% over the past year, including dividends.
- Overall, Oncoinvent ranks better than 36% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 99.9%. The price is 100.0% below its peak now.
What do analysts think of Oncoinvent?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 36% of Nordic stocks.
No. 89 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 96 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.03
- Asset turnoverSales divided by everything the company owns0.04
- Return on equityProfit divided by equity−133.4%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 177 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity4.0
- P/SPrice divided by sales60.1
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 59 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−14.4%
- 6 months+52.5%
- 9 months+56.5%
- 12 months+41.8%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Oncoinvent
Oncoinvent ASA is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 42 employees.
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway.


See the full analysis of Oncoinvent.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card